Patients in Sativex Trials Did Not Become Unblinded, Confirming Reliable Results | Research

The takeaway

A statistical analysis of 666 patients across three Phase III Sativex trials found no evidence that patients figured out whether they received the drug or placebo, confirming the validity of the trial results.

Read this if you want to understand whether Sativex clinical trial results are trustworthy.

No evidence of unblinding across 666 patients in 3 Phase III trials

What the researchers found

The researchers addressed a critical concern about cannabis medicine trials: could patients tell whether they received the active drug based on side effects or prior cannabis experience, thereby biasing self-reported outcomes? Analyzing 666 patients across three Phase III placebo-controlled studies, they found no significant relationship between Sativex's effect on spasticity and either prior cannabis use or the occurrence of typical cannabis-related adverse events.

There was also no significant relationship between prior cannabis use and adverse event incidence, or between prior cannabis use and Sativex dosing. The results indicate that the blinding was maintained and the treatment differences were genuine.

Why it matters

Maintaining blinding in cannabis trials is uniquely challenging because patients may recognize the drug's psychoactive effects. This study provided evidence that Sativex trials successfully maintained blinding, strengthening confidence in the reported efficacy results.

The numbers in context

666 patients across 3 Phase III trials. No significant relationship between treatment effect and prior cannabis use. No significant relationship between treatment effect and typical adverse events. No significant relationship between prior cannabis use and dose.

How the study worked

Post-hoc analysis of 666 patients from three Phase III placebo-controlled RCTs of Sativex for MS spasticity. General linear modeling tested whether prior cannabis experience or typical adverse events predicted treatment effects on patient-reported spasticity outcomes.

What this study cannot tell us

Statistical analysis can demonstrate lack of association but cannot prove that no individual patient became unblinded. The approach assumes that unblinding would manifest as measurable relationships between specific factors and outcomes. Some degree of unblinding below the detection threshold of the analysis may have occurred.

How to read the evidence

Methodologically rigorous analysis of three large RCTs; strong evidence for trial validity.

When this study was published

Published in 2012. Blinding assessment has become an increasingly recognized component of cannabis trial methodology.

The bigger picture

The integrity of blinding is fundamental to clinical trial validity. This study developed a novel statistical approach to assess blinding that could be applied to other trials where the active drug has a recognizable side effect profile.

Questions still open

Could this blinding assessment methodology be standardized for all cannabis clinical trials? Would similar results be found in trials of higher-THC formulations? Should blinding assessment become a routine part of cannabis trial reporting?

Common questions

Why is blinding a concern in cannabis trials?

Cannabis products can produce noticeable effects like mild euphoria, dizziness, or changes in perception. If patients realize they received the active drug, they might report greater symptom improvement due to expectations (placebo effect) rather than the drug's actual therapeutic action. This study tested whether that happened and found no evidence of it.

What does this mean for Sativex's efficacy?

It means the symptom improvements reported in Sativex trials are more likely to reflect genuine therapeutic effects rather than bias from patients knowing they received the active drug. The treatment differences between Sativex and placebo were not driven by unblinding.

Read the original research

Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach.

Trials, 13, 189

View on PubMed ↗Publisher’s paper ↗

Citation

Wright, Stephen; Duncombe, Paul; Altman, Douglas G. (2012). Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach.. Trials, 13, 189. https://doi.org/10.1186/1745-6215-13-189